2-chloro-1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-ethanone | 422270-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-ethanone
• 英文别名: 2-Chloro-1-{(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl}ethan-1-one；2-chloro-1-[(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]ethanone
• CAS: 422270-30-2
• 化学式: C₁₄H₁₈ClFN₂O
• 分子量: 284.761
• InChiKey: MZTKTSQWYIUMEO-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-ethanone 在 盐酸 、 tin(ll) chloride 、 肼 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-(2-Amino-4-chloro-phenylamino)-1-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone
  参考文献：
  名称：

  Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis

  摘要：

  Cinnamides as novel CCR1 antagonist chemotypes are described with high affinity to human and rodent receptors. A1B1 and A4B7 showed oral activity in the mouse collagen induced arthritis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.057
• 作为产物：
  描述：

  4-氟氯苄 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-chloro-1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-ethanone
  参考文献：
  名称：

  Structure–activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

  摘要：

  Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCRI antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.104

文献信息

• Methods of using piperazine derivatives
  申请人：Pfizer Inc

  公开号：US20040092529A1

  公开（公告）日：2004-05-13

  The present invention relates to compounds of the formula I 1 and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.

  本发明涉及公式I1的化合物及其药学上可接受的形式；其中X、Y、a、b、c、d、R1、R2、R3、R4和R5如本文所定义。此外，本发明还涉及包含公式I的化合物和药学上可接受的载体的药物组合物。此外，本发明还涉及使用本文所述的化合物和组合物治疗或预防哺乳动物中可通过拮抗CCR1受体治疗或预防的疾病或状况的方法。
• Novel sulfonic acid derivatives
  申请人：——

  公开号：US20030083335A1

  公开（公告）日：2003-05-01

  A compound of the formula 1 or the pharmaceutically acceptable salt thereof; wherein X, Y, a, b, c, d, R 1 , R 2 , R 3 and R 5 are as defined above useful to treat inflammation and other immune disorders.

  该化合物的公式为1或其药学上可接受的盐；其中X、Y、a、b、c、d、R1、R2、R3和R5的定义如上所述，有助于治疗炎症和其他免疫性疾病。
• Methods of using sulfonic acid derivatives
  申请人：Pfizer Inc

  公开号：US20040116441A1

  公开（公告）日：2004-06-17

  The present invention relates to methods of using CCR1 antagonists as immunomodulatory agents. In particular, the methods relate to using compounds of the formula 1 or the pharmaceutically acceptable salt thereof; wherein X, Y, a, b, c, d, R 1 , R 2 , R 3 and R 5 are as defined herein.

  本发明涉及使用CCR1拮抗剂作为免疫调节剂的方法。特别地，所述方法涉及使用式1的化合物或其药学上可接受的盐；其中X、Y、a、b、c、d、R1、R2、R3和R5的定义如本文所述。
• Novel piperazine derivatives
  申请人：——

  公开号：US20040034034A1

  公开（公告）日：2004-02-19

  The present invention relates to compounds of the formula I 1 and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.

  本发明涉及公式I1的化合物及其药学上可接受的形式；其中X、Y、a、b、c、d、R1、R2、R3、R4和R5的定义如本文所述。此外，本发明还涉及包含公式I的化合物和药学上可接受的载体的制药组合物。此外，本发明还涉及使用上述化合物和组合物治疗或预防哺乳动物中可以通过拮抗CCR1受体来治疗或预防的疾病或症状的方法。
• Piperazine derivatives
  申请人：——

  公开号：US07098212B2

  公开（公告）日：2006-08-29

  The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.

  本发明涉及公式I及其药学上可接受的形式的化合物；其中X、Y、a、b、c、d、R1、R2、R3、R4和R5如本文所定义。此外，本发明还涉及包含公式I化合物和药学上可接受的载体的制药组合物。此外，本发明还涉及使用所述化合物和组合物治疗或预防哺乳动物中可通过拮抗CCR1受体治疗或预防的疾病或病症的方法。